The estimated Net Worth of Reshma Rangwala is at least 530 千$ dollars as of 22 April 2024. Dr Rangwala owns over 6,789 units of Aravive Inc stock worth over 13,717$ and over the last 4 years he sold ARAV stock worth over 60,892$. In addition, he makes 455,807$ as Chief Medical Officer at Aravive Inc.
Dr has made over 3 trades of the Aravive Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently he sold 6,789 units of ARAV stock worth 7,943$ on 22 April 2024.
The largest trade he's ever made was selling 21,636 units of Aravive Inc stock on 29 February 2024 worth over 25,530$. On average, Dr trades about 3,520 units every 37 days since 2020. As of 22 April 2024 he still owns at least 342,931 units of Aravive Inc stock.
You can see the complete history of Dr Rangwala stock trades at the bottom of the page.
Dr. Reshma Rangwala M.D., Ph.D. is the Chief Medical Officer at Aravive Inc.
As the Chief Medical Officer of Aravive Inc, the total compensation of Dr D at Aravive Inc is 455,807$. There are 3 executives at Aravive Inc getting paid more, with Gail McIntyre having the highest compensation of 713,495$.
Dr D is 43, he's been the Chief Medical Officer of Aravive Inc since . There are 9 older and 1 younger executives at Aravive Inc. The oldest executive at Aravive Inc is Fredric Eshelman, 72, who is the Independent Chairman of the Board.
Reshma's mailing address filed with the SEC is C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, NEWTON, MA, 02459.
Over the last 6 years, insiders at Aravive Inc have traded over 107,045$ worth of Aravive Inc stock and bought 151,333 units worth 1,102,898$ . The most active insiders traders include Srinivas Akkaraju、Fredric N Eshelman Ventures...、Shahzad Malik. On average, Aravive Inc executives and independent directors trade stock every 75 days with the average trade being worth of 11,962$. The most recent stock trade was executed by Fredric N Eshelman Ventures... on 1 April 2022, trading 4,545,455 units of ARAV stock currently worth 181,818$.
versartis, inc. (nasdaq: vsar) is an endocrine-focused biopharmaceutical company developing novel, long-acting medicines to transform treatment for patients with endocrine disorders. the company is led by a management team with rich experience and expertise discovering, developing and commercializing innovative therapeutics for the life sciences industry. versartis’ mission is to develop, manufacture and commercialize novel therapeutics to improve and transform treatment for patients with orphan endocrine disorders. learn more at www.versartis.com.
Aravive Inc executives and other stock owners filed with the SEC include: